Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Naval G DaverAlexander E PerlJoseph MalyMark LevisEllen RitchieMark R LitzowJames McCloskeyCatherine C SmithGary SchillerTerrence BradleyRamon V TiuKiran NaqviMonique DailDeanna BrackmanSatya SiddaniJing WangBrenda J ChylaPaul LeeJessica K AltmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
molecular response rates regardless of prior FLT3 inhibitor exposure. Dose interruptions were needed to mitigate myelosuppression.